All In Biotech

Drug Trial Radar · NCT07901933

Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Oct 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Cajal Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b, randomized, double-blinded, placebo-controlled study of CTX001 in participants with anemia and chronic kidney disease who are not on dialysis.

Conditions

  • Chronic Kidney Disease
  • Anemia

Interventions

  • PlaceboDrug

    Matching placebo administered orally once daily for 29 days.

  • CTX001Drug

    CTX001 administered orally at the assigned cohort dose once daily for 29 days.

  • Ferrous SulfateDrug

    Ferrous sulfate administered orally once daily for 29 days in both treatment arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: From first administration of study intervention through the end of study participation, around Day 36.
  2. Incidence of Serious TEAEsTime frame: From first administration of study intervention through the end of study participation, around Day 36.
  3. Incidence of Clinically Significant Changes in Physical ExaminationTime frame: From first administration of study intervention through the end of study participation, around Day 36.
  4. Incidence of Clinically Significant Changes in Safety Laboratory ValuesTime frame: From first administration of study intervention through the end of study participation, around Day 36.
  5. Incidence of Clinically Significant Changes in Vital SignsTime frame: From first administration of study intervention through the end of study participation, around Day 36
  6. Incidence of Clinically Significant Changes in ElectrocardiogramsTime frame: From first administration of study intervention through the end of study participation, around Day 36

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Renal Research Gosford

    Gosford, New South Wales, Australia

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • AOVO Clinical Trials

    Southport, Queensland, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.